Patent Term Extension: Challenges with Defining and Claiming Approved Biologics

Key Takeaways

• Biologics lack clear “active ingredient” definition for PTE.
• FDA/USPTO may reject cell‑based claims as active ingredient.
• Only one PTE allowed; choose patent carefully.
• Early alignment of regulatory and patent language mitigates risk.
• Case law evolution will affect future biosimilar litigation.

Summary

Patent term extension (PTE) offers up to five extra years of exclusivity for FDA‑approved drugs, but biologics present a unique hurdle because the law hinges on defining the “active ingredient.” Unlike small molecules, biologics are large, variable structures, making it unclear whether the protein, its modifications, or an entire conjugate qualifies. Recent USPTO rulings on cell‑based therapies such as YESCARTA illustrate how divergent interpretations can determine whether a PTE is granted. Consequently, developers must align patent claims with regulatory descriptions early to secure the full benefit of PTE.

Pulse Analysis

The statutory framework for patent term extension was crafted for small‑molecule drugs, where a single, well‑characterized chemical entity serves as the active ingredient. Biologics, by contrast, comprise proteins, nucleic acids, or cell‑based products whose functional activity depends on higher‑order structures, post‑translational modifications, or even patient‑specific components. This mismatch forces the USPTO and courts to interpret the law on a case‑by‑case basis, creating uncertainty for innovators who rely on PTE to recoup R&D investments.

Recent USPTO decisions highlight the practical consequences of this uncertainty. In the YESCARTA® CAR‑T cell therapy, the applicant initially claimed the engineered T cells as the active ingredient, but the USPTO rejected that view, arguing patient‑specific variability. The agency ultimately approved the DNA sequence encoding the CAR, a narrower definition that still secured extension. By contrast, LAVIV® succeeded by listing fibroblast cells themselves as the active ingredient. These divergent outcomes underscore how the precise language used in Biologics License Applications and patent claims can make or break a PTE request, influencing both the scope of protection and the likelihood of future biosimilar challenges.

For companies developing biologics, the prudent path is to embed PTE considerations at the earliest stages of product design. Coordinated efforts between regulatory and patent counsel should ensure that the active ingredient is described consistently across the BLA, labeling, and patent specifications, balancing breadth against the risk of USPTO rejection. As the Federal Circuit begins to address biologic‑specific active‑ingredient questions, firms that have already aligned their portfolios will be better positioned to defend extensions and maximize revenue during the critical post‑approval exclusivity window.